Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics
Sign Up to like & getrecommendations! Published in 2017 at "Therapeutic Advances in Cardiovascular Disease"
DOI: 10.1177/1753944717718718
Abstract: Background: Clopidogrel is by far the most prescribed platelet adenosine diphosphate (ADP) antagonist in Puerto Rico despite the advent of newer agents (prasugrel and ticagrelor). Given the paucity of data on clopidogrel responsiveness in Hispanics,… read more here.
Keywords: clinical determinants; puerto rican; platelet reactivity; patients clopidogrel ... See more keywords
PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel—A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Physiology"
DOI: 10.3389/fphys.2018.01550
Abstract: Background: Clopidogrel and proton pump inhibitors (PPIs) are metabolized by cytochrome P450 enzymes. Contradictory results have been reported on possible complications of simultaneous PPI and clopidogrel use. Our aim was to investigate the clinical relevance… read more here.
Keywords: review meta; analysis; systematic review; patients clopidogrel ... See more keywords
Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study.
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Saudi medicine"
DOI: 10.5144/02564947.2019.82
Abstract: BACKGROUND Recent studies suggest a higher risk of adverse cardiovascular outcome and mortality in patients co-prescribed clopidogrel with proton pump inhibitors (PPI). OBJECTIVE Investigate the impact of concomitant prescription of clopidogrel and PPI on 30-day… read more here.
Keywords: one year; mortality; patients clopidogrel; plus ppi ... See more keywords